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AbstrAct
TRAIL can induce apoptosis in some cancer cells and is an immune effector in the 
surveillance and elimination of developing tumors. Yes, some cancers are resistant 
to TRAIL. Delphinidin, a polyphenolic compound contained in brightly colored fruits 
and vegetables, has anti-inflammatory, anti-oxidant, and anti-tumorigenic activities. 
Here we showed that delphinidin sensitized TRAIL-resistant human prostate cancer 
cells to undergo apoptosis. Cells treated with delphinidin and TRAIL activated the 
extrinsic and intrinsic pathways of caspase activation. TRAIL-induced apoptosis in 
prostate cancer cells pretreated with delphinidin was dependent on death receptor 
5 (DR5) and downstream cleavage of histone deacetylase 3 (HDAC3). In conclusion, 
delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis by inducing 
DR5, thus causing caspase-mediated HDAC3 cleavage. Our data reveal a potential 
way of chemoprevention of prostate cancer by enabling TRAIL-mediated apoptosis.
INtrODUctION
Prostate cancer is one of the most frequently 
diagnosed, non-cutaneous neoplasms in men and the 
second leading cause of cancer-related mortality among 
men in the United States. Prostate cancer is unique among 
human cancers because of its striking age-dependent 
incidence and variable penetrance. Genetic, epigenetic, 
and environmental factors, including diet, also contribute 
to the prostate carcinogenesis process [1, 2]. In other 
words, the development of prostate cancer in humans 
presents as a multistage process, involving a small latent 
carcinoma of low histological grade at its onset, which 
later progresses to a large metastatic lesion [3]. However, 
therapeutic strategies for this disease are limited because 
chemotherapy and radiation therapy are largely ineffective, 
and metastatic disease frequently develops even after 
potentially curative surgery [4-6]. Therefore, developing a 
novel therapeutic strategy for prostate cancer has become 
an important medical need.
Tumor necrosis factor - related apoptosis - inducing 
ligand (TRAIL) is a member of the tumor necrosis factor 
(TNF) family of cytokines. TRAIL exerts proapoptotic 
effects on malignant cells without any harmful effects to 
normal cells. Endogenous TRAIL triggers death signaling 
via receptor-mediated apoptosis through its interaction 
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with these death receptors (DRs) on the surface of cancer 
cells [7]. Five members of the death receptor family have 
been identified that can bind TRAIL. The death receptors, 
DR4 (TRAIL-R1) and DR5 (TRAIL-R2), contain both 
two cysteine-rich extracellular TRAIL-binding domains 
and a cytoplasmic death domain that are required for 
transmitting a cytotoxic signal [8, 9]. The decoy receptors, 
DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4), also possess 
binding ability for TRAIL, but they do not transmit 
apoptotic signals due to a nonfunctional death domain [10, 
11]. Finally, TRAIL initiates programmed cell death upon 
binding to DR4 and/or DR5, which induces clustering 
of the bound DRs (forming a microaggregate within the 
cell membrane), and promotes the recruitment of the 
adaptor molecule FADD (FAS-associated death domain). 
This results in the formation of DISC (death inducing 
signaling complex) and subsequent effector caspases. 
TRAIL-mediated apoptosis can also be induced by the 
intrinsic pathway, with the implication of mitochondrial 
dysfunction, and the extrinsic pathway [12]. Caspase-8, 
which contains a death effector domain, is activated by a 
death receptor signaling pathway, and caspase-9, which 
contains a caspase activation and recruitment domain 
(CARD), is activated by a mitochondrial death signaling 
pathway [13]. The link between the extrinsic and intrinsic 
signaling pathways is formed by the BID (BH3-interacting 
domain death agonist) protein, which is cleaved and 
activated by caspase-8. Then, active caspase 8 cleaves 
and directly activates downstream effector caspases (3, 6 
and 7), which ultimately cut vital cellular substrates and 
cause apoptosis [14, 15]. BCL-2 family proteins, which 
comprise both anti-apoptotic members such as BCL-2 and 
MCL-1 and pro-apoptotic molecules such as BAX, play 
an important role in the regulation of the mitochondrial 
apoptotic pathway [16]. TRAIL treatment results in up-
regulation of DR5 expression, activation of caspase-8 
and BID, leading to BAX conformational changes and 
translocation to the mitochondria. This, in turn, causes a 
loss of mitochondrial membrane potential and release of 
cytochrome c into the cytoplasm, followed by activation 
of caspase-3, and induction of caspase-dependent 
apoptosis [17]. Inhibitor of Apoptosis proteins (IAPs) 
can block executioner caspases. Specifically, XIAP and 
survivin are potent inhibitors of caspase 9, while cIAP-2 
and XIAP can inhibit caspases 3 and 7 [18, 19]. p53 can 
act in both the extrinsic pathway to up-regulated TRAIL 
receptors directly in a p53-dependent manner or to activate 
pro-apoptotic elements, such as BAX through the intrinsic 
apoptotic pathway [20]. More recently, enhancement of 
p53 acetylation levels strongly correlates with protein 
stabilization and activation in response to cellular stress 
and is indispensable for p53 transcriptional activity [21, 
22].
However, some tumor cells - including prostate 
cancer and gliomas - are resistant to TRAIL-induced 
apoptosis [23-26]. Failure to undergo apoptosis has been 
implicated in the resistance of cancer cells to TRAIL 
surveillance, and, therefore, in tumor development 
[14]. In addition, an obstacle to effective therapy is that 
prostate cancer, similar to many other cancers, develops 
resistance to TRAIL [27-29]. Thus, researchers are 
currently seeking to identify TRAIL sensitizers which is 
capable of overcoming TRAIL resistance in cancer cells. 
Novel agents, such as natural compounds, are needed 
to overcome this resistance and to improve TRAIL 
efficacy. Recently, a variety of agents, such as various 
types of isoflavones [30], ursolic acid [31], carnitine [32], 
salirasib [33], monensin [34], and 2-tellurium-bridged 
β-cyclodextrin [35], have been reported to sensitize tumors 
to TRAIL-induced apoptosis. Recently, cancer prevention 
research reports have shown that chemopreventive agents, 
such as curcumin, EGCG (epigallocatechin gallate), and 
resveratrol, have the therapeutic potential to sensitize 
prostate cancer cells to TRAIL [36-38]. In this study, we 
examined this hypothesis to determine whether delphinidin 
enhances the therapeutic potential of TRAIL and induces 
apoptosis of TRAIL-resistant prostate cancer LNCaP cells.
Furthermore, resistance to TRAIL is an important 
therapeutic problem that may be resolved by combination 
treatments, but it act by various mechanisms, including 
the restoration of caspase-8 expression or decrease in 
c-FLIP levels [39, 40]. Because most agents used in 
such combinations are inherently toxic, it is imperative 
to find nontoxic agents, such as HDAC inhibitors 
(HDACi), which have recently entered clinical trials and 
exert their antitumor effects by inducing growth arrest, 
differentiation, and apoptosis [41-44]. To date, eighteen 
distinct HDACs have been identified and classified into 
four groups based on their structural divergence, namely, 
class I, II, III, and IV HDACs [45, 46]. There are three 
classes of mammalian HDAC enzymes, class I comprising 
HDAC1, HDAC2, HDAC3, and HDAC8; class II HDACs 
comprising HDAC4, HDAC5, HDAC6, HDAC7, 
HDAC9, and HDAC10; and a third class of NAD-
dependent SIR2 deacetylases [43-45]. These HDACs 
are involved in modulating most key cellular processes, 
including apoptosis, autophagy, transcriptional regulation, 
metabolism, DNA damage repair, cell cycle control, 
senescence, and chaperone function [47]. However, 
HDACs have been found to function incorrectly in cancer. 
Therefore, HDAC inhibition by an HDAC inhibitor or by 
HDAC cleavage has been explored as a chemotherapeutic 
strategy to interfere with aberrant HDAC activity in 
human cancers. Several studies have demonstrated that a 
combination strategy of an HDAC inhibitor with a TRAIL 
sensitizer has emerged as a potent strategy to prime cancer 
cells to TRAIL-mediated apoptosis in a variety of human 
cancers [48]. Recently, HDAC cleavage has been shown to 
play an important role in apoptosis in response to various 
cellular stimuli. For example, the apoptosis induced by 
cleaved HDAC3 or enhanced by c-JUN deficiency during 
osmotic stress is suppressed by exogenous expression of 
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c-JUN, indicating that the down-regulation of c-JUN by 
HDAC3-dependent transcriptional repression plays a role 
in regulating cell survival and apoptosis [49]. Caspase-
dependent HDAC3 degradation, which is involved in the 
regulation of E2F-1 transcription, has also been observed 
in neuronal apoptosis [50]. Notably, Fabrice E and 
colleagues demonstrated the role of HDAC3 in apoptosis 
control. They showed that C-terminal cleavage of HDAC3 
is caspase dependent and accumulates in the cytoplasm. 
The cleavage and cytoplasm re-localization of HDAC3 
caused by apoptosis stimuli induces apoptosis of cells via 
the activation of proapoptotic genes and the inhibition 
of anti-apoptotic genes [51]. Thus, cleaved HDAC3 is 
indispensable for inducing cell apoptosis. 
Anthocyanins are naturally occurring flavonoids 
that are responsible for the bright colors of many fruits 
and vegetables. Anthocyanins are organic compounds, 
which are derivatives of the glycosylation of aglycon 
anthocyanidin, and more than 500 kinds of compounds, 
with differences in the number of added sugars, are 
estimated to exist. As representatives of anthocyanidins, 
delphinidin, pelargonidin, cyanidin, and malvidin are 
naturally occurring [52-54]. Delphinidin, one of the major 
anthocyanidins present in these fruits and vegetables, is 
a diphenylpropane-based polyphenolic ring structure 
that carries a positive charge on its central ring [55]. 
Delphinidin possesses anti-oxidant [56], anti-inflammatory 
[57], anti-angiogenic [58] and anti-mutagenic activity 
[59], and was recently reported to inhibit invasion of 
breast cancer cells [60]. Other studies have revealed 
that delphinidin inhibits proliferation and induces 
apoptosis in many different cancer models including 
colon, uterine, breast, and prostate [61-64]. However, dd 
effects of delphinidin on TRAIL-induced apoptosis and 
the underlying molecular mechanisms for those effects in 
prostate cancer cells. 
In this study, we demonstrated that delphinidin 
potently sensitized human prostate cancer cells to TRAIL-
mediated apoptosis via DR5 induction and the caspase-
dependent pathway. Furthermore, we showed for the first 
time that cleavage of HDAC3 had a critical role in this 
caspase-dependent apoptotic pathway on TRAIL-induced 
apoptosis in the presence of delphinidin. Therefore, The 
combination delphinidin with TRAIL could be attractive 
strategy for the treatment of TRAIL-resistant prostate 
cancer.
rEsULts
Delphinidin enhances trAIL-mediated apoptosis 
in prostate cancer cells
LNCaP cells are more refractory to TRAIL-
induced apoptosis than Du145 cells. Using the MTT 
assay and western blot analysis to assess PARP cleavage, 
we confirmed this differential sensitivity to the anti-
proliferative effects and apoptosis in a dose- and time-
dependent manner, respectively. As shown in Fig. 1B and 
1C, TRAIL treatment for 12 h LNCaP cells were refractory 
to a TRAIL-induced anti-proliferative effect to a dose as 
high as 100 ng/ml, while treatments with 50 ng/ml TRAIL 
resulted in approximately 50% inhibition of cell growth in 
Du145 cells. Apoptosis was activated in both LNCap and 
Du145 cells upon treatment with 150 ng/ml and 50 ng/
ml of TRAIL for 12 h, respectively, as confirmed by the 
results for PARP cleavage (Fig. 1D).
We first measured the effect of delphinidin on cell 
viability and PARP cleavage using western blot analysis 
in human prostate cancer cell lines. We examined whether 
delphinidin induced apoptosis in LNCaP and Du145 cells. 
Cells were treated with various low-dose concentrations 
(0-90 μM) of delphinidin for 12 h. We then observed that 
low-dose delphinidin did not inhibit cell viability (Fig. 
2A) and PARP cleavage (Fig. 2B) in LNCaP and Du145 
cells, respectively. Next, we examined the effect on cell 
viability and PARP cleavage of combining delphinidin 
(0-30 μM) with 50 ng/ml TRAIL. Delphinidin strongly 
synergized with TRAIL to induce an anti-proliferative 
effect in a dose-dependent manner (Fig. 2C). As shown 
in Fig. 2D, in TRAIL-resistant LNCaP cells no cleavage 
of PARP occurred upon treatment with 50 ng/ml TRAIL 
alone, but TRAIL treatment cleaved PARP in the presence 
of 10 μM delphinidin. In contrast, in TRAIL-sensitive 
Du145 cells PARP cleavage was induced by TRAIL 
treatment even in the absence of delphinidin. To further 
investigate the anti-proliferative and proapoptotic effects 
of delphinidin, we examined whether delphinidin could 
sensitize LNCaP and Du145 cells to TRAIL-mediated 
cell growth inhibition and to induce apoptosis. LNCaP 
and Du145 cells were treated for 12 h with delphinidin 
(30 μM) along with various concentrations of TRAIL. 
Figure 2E shows that after 12 h delphinidin treatment 
synergistically sensitized the anti-proliferative effect in 
response to TRAIL. The co-treatment with delphinidin 
(30 μM) and various concentrations of TRAIL similarly 
induced PARP cleavage in TRAIL-sensitive Du145 
cells and TRAIL-resistant LNCaP cells (Fig. 2F). These 
results suggest that delphinidin increases the apoptotic 
ability of TRAIL in prostate cancer cells. In subsequent 
experiments, we used TRAIL-resistant LNCaP cells to 
reveal the delphinidin-induced sensitization mechanisms 
of TRAIL-mediated apoptosis.
Delphinidin accelerates trAIL-induced apoptosis 
by activating a caspase-dependent pathway in 
LNcaP cells
To observe whether the combination of delphinidin 
with TRAIL leads to activation of apoptosis in TRAIL-
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Figure 2: Delphinidin sensitizes LNcaP and Du145 cells with trAIL-mediated apoptosis. (A and b) Delphinidin has 
anti-proliferative and proapoptotic effects in prostate cancer cells. LNCaP and Du145 cells were treated with different concentration of 
delphinidin (DEL) (0, 30, 60, 90 μM) for 12 h. Delphinidin had no effect on cell viability at these concentrations as measured by an MTT 
assay (A) and western blot analysis against apoptosis marker PARP showed no cleavage (b). (C–F) Delphinidin sensitized LNCaP and 
Du145 cells to TRAIL-mediated apoptosis. LNCaP and Du145 cells were treated with different concentrations of delphinidin (0, 10, 30, 50 
µM) and/or a fixed concentration of TRAIL (50 ng/ml) for 12 h. Combined treatment increased cell death as measured by an MTT assay 
(c) and PARP cleavage (D). Subsequently, LNCaP and Du145 cells were treated with different concentrations of TRAIL (0, 50, 100, 150 
ng/ml) and a fixed concentration of delphinidin (30 μM) for 12 h. Combined treatment increased cell death (E) and PARP cleavage (F). The 
data are expressed as the mean ± SD for triplicates.
Figure 1: Delphinidin sensitizes trAIL-mediated apoptosis in human prostate cancer cells. (A) The chemical structure of 
delphinidin. (B and C) Anti-proliferation effect of TRAIL in human prostate cancer cell lines. LNCaP (b) and Du145 cells (c) were treated 
with TRAIL in a dose- and time-dependent manner. LNCaP and Du145 cells were treated with different concentrations of TRAIL (0, 25, 50, 
100, 150 ng/ml) for the indicated times (4, 8, 12 h) and cell viability was measured by MTT assay. The data are expressed as the mean ± SD 
for triplicates. (D) TRAIL induced apoptosis in prostate cancer cell lines. LNCaP and Du145 cells were treated with different concentration 
of TRAIL (0, 50, 100, 150 ng/ml) for 12 h. Cell viability was measured by a MTT assay.
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resistant LNCaP cells, apoptotic cell death and nuclear 
fragmentation/shrinkage was monitored by cell 
morphology and DAPI staining. As shown in Fig. 3A, the 
morphology of LNCaP cells was significantly altered by 
the combination of TRAIL with delphinidin, but not by 
either individual treatment. The nuclear morphology in 
DAPI-stained cells was destroyed during TRAIL-mediated 
apoptosis in the presence of delphinidin (Fig. 3B).
To further explore the apoptosis-inducing 
mechanism, we examined the activation and expression 
of caspase proteins. Preferentially, to determine whether 
combined treatment with delphinidin and TRAIL induces 
caspase-dependent apoptosis, LNCaP cells were incubated 
for 12 h with 50 ng/ml TRAIL and 30 µM delphinidin 
in the presence or absence of zVAD, a general caspase 
inhibitor. As shown in Figure 3C, treatment with zVAD 
remarkably reduced the ability of delphinidin to sensitize 
LNCaP cells to TRAIL-induced apoptosis. As expected 
from the zVAD antagonism, co-treatment with TRAIL and 
delphinidin induced a significant cleavage of caspase-3 
and caspase-7 on western blot analysis (Fig. 3D). The 
levels of cleaved initiator caspase-8 and caspase-9 were 
enhanced by co-treatment with TRAIL and delphinidin, 
and were completely inhibited by zVAD (Fig. 3D). As 
shown in Fig. 3E-G, treatment with zVAD dramatically 
repressed the activity of caspase-3/7, caspase-8 and 
caspase-9 in LNCaP cells and attenuated the sensitization 
induced by the combined treatment with TRAIL and 
delphinidin.
Figure 3: trAIL and delphinidin induces apoptosis via activation of caspases in LNcaP cells. (A and b) LNCaP cells 
were treated with TRAIL (TR, 50 ng/ml) and/or delphinidin (DEL, 30 µM) for 12 h. (A) The cell morphology was visualized by an 
inverted microscope (magnification ×100). (B) By DAPI staining, the cells clearly show condensed chromatin or fragmented nuclei 
which were taken as apoptotic bodies (magnification ×1000). (c and D) TRAIL-mediated apoptosis with delphinidin was suppressed 
by caspase inhibitor zVAD. LNCaP cells were pretreated for 30 min with or without zVAD (40 μM) before TRAIL (50 ng/ml) and/or 
delphinidin (30 µM) treatment for 12 h. The increased apoptosis from combination treatment was blocked by zVAD (C) and the levels of 
caspase-8, caspase-9, and cleaved caspase-3 and caspase-7 were reduced by zVAD treatment on western blot analysis (D). (E-G) TRAIL 
and delphinidin dramatically induced activation of caspases in LNCaP cells. LNCaP cells were pretreated for 30 min with or without zVAD 
(40 μM) before TRAIL (50 ng/ml) and/or delphinidin (30 µM) treatment for 12 h. After incubation, the activities of caspase-3/7, caspase-8, 
and caspase-9 were inhibited by zVAD treatment. All data are expressed as the mean ± SD for triplicates (*P<0.05 vs. -TRAIL/-DEL; 
**P<0.05 vs. with +TRAIL/+DEL).
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trAIL-induced apoptosis in cells pretreated 
with delphinidin involves both the Dr5 and the 
intrinsic apoptotic pathways
Because DR5 on the cell surface trigger apoptosis 
dependent on TRAIL binding, we investigated whether 
delphinidin induced DR5 protein expression in a dose-
dependent manner in LNCaP and Du145 cells. As 
shown in Fig. 4A, delphinidin treatment up-regulated 
the expression of DR5 protein in a dose-dependent 
manner, siRNA-mediated suppression of DR5 effectively 
blocked delphinidin-stimulated TRAIL-induced caspase-3 
activation (Fig. 4B, upper) and apoptosis (Fig. 4C). 
Next, we investigated whether the modulation of BAX 
proteins is involved in the sensitization of LNCaP cells to 
TRAIL-induced apoptosis by delphinidin. Co-treatment of 
LNCaP cells with delphinidin and TRAIL resulted in the 
up-regulation of BAX expression, and siRNA-mediated 
knock-down of BAX markedly inhibited delphinidin-
stimulated TRAIL-induced caspase-3 activation (Fig. 
4B, bottom). Because the combined treatment with 
TRAIL and delphinidin leads to the modulation of 
BCL-2 family proteins related to the intrinsic apoptotic 
pathway - including the IAPs, MCL-1, and p21 - we 
evaluated the mRNA expression of these proteins in 
LNCaP cells. As shown in Fig. 4D, co-treatment resulted 
in the up-regulation of BAX and p21 as well as DR5 in 
LNCaP cells; whereas, it significantly reduced the mRNA 
expression level of XIAP, cIAP-2, Bcl-2, survivin and 
MCL-1.
Figure 4: trAIL and delphinidin activate Dr5 expression and intrinsic apoptotic pathway. (A) Delphinidin induces DR5 
in LNCaP and Du145 cells. LNCaP and Du145 cells were treated for 12 h with different concentration of delphinidin (0, 10, 30, 50 µM), 
and western blot analysis was performed using antibodies against DR5. (B and C) DR5 and BAX expression is critical for the sensitization 
of TRAIL-mediated apoptosis. LNCaP cells transfected with the scrambled siRNA, DR5 siRNA, or BAX siRNA were further treated with 
30 μM delphinidin and 50 ng/ml TRAIL for 12 h. (b) Western blot analysis demonstrated inhibition of caspase-3 cleavage by knockdown of 
DR5 or BAX and (c) their corresponding antiapoptotic effects. The apoptotic cell death was determined by MTT assay (left) and TUNEL 
assay (right) kit as described in Materials and Methods. (D) Co-treatment of delphinidin and TRAIL regulates the expression of various 
apoptosis-related genes at transcriptional level. LNCaP cells were treated with TRAIL (T, 50 ng/ml) and/or delphinidin (D, 30 µM) for 12 h. 
The expression level of each gene was analyzed by qRT-PCR using total mRNA from LNCaP cells, treated with delphinidin and/or TRAIL, 
and compared with control LNCaP cells. Fold-change was calculated by 2--△△Ct relative quantitative analysis. The data are expressed as the 
mean ± SD for triplicates (*P<0.05 vs. -TRAIL/-DEL).
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HDAc3 cleavage is critical for the regulation 
of apoptosis-related proteins in delphinidin-
stimulated trAIL-mediated apoptosis
The epigenetic changes of apoptosis are attended 
by chromatin condensation and chromatin breaks. As 
shown in Fig. 5A, combined treatment with delphinidin 
and TRAIL resulted in the down-regulation of HDAC3 
expression which is proportional to an increasing 
concentration of delphinidin, but neither delphinidin nor 
TRAIL alone down-regulated HDAC3 expression. In 
contrast, the expression levels of other class I HDACs 
HDAC1, HDAC2 and HDAC8, were not altered. As 
shown in Fig. 5B, siRNA-mediated knockdown of 
HDAC3 expression induced PARP cleavage the presence 
of TRAIL while HDAC3 silencing induced PARP cleavage 
to a lesser degree also in the absence of TRAIL. However, 
siRNA-mediated knockdown of other class I HDACs had 
no effect PARP cleavage regardless of treatment with 
Figure 5: HDAc3 cleavage contributes to the regulation of apoptosis-related proteins on co-treatment delphinidin and 
trAIL. (A) HDAC3 is cleaved by co-treatment of delphinidin and TRAIL. LNCaP cells were incubated with different concentration of 
delphinidin (0, 10, 30, 50 µM) with or without TRAIL (50 ng/ml) for 12 h. Western blot analysis was performed by using antibodies against 
HDAC1, HDAC2, HDAC3 or HDAC8. (b) Knockdown of HDAC3 sensitizes to TRAIL. LNCaP cells transfected with the indicated siRNA 
(scrambled siRNA, HDAC1, HDAC2, HDAC3, or HDAC8). Following transfection, cells were also exposed for a further 12 h to TRAIL (50 
ng/mL), and analyzed by western blot with anti-HDAC1, HDAC2, HDAC3, HDAC8, or PARP antibodies. (c) Down-regulation of HDAC 
activity is induced by co-treatment of delphinidin and TRAIL. LNCaP cells were incubated with different concentrations of delphinidin (0, 
10, 30, 50 µM) with or without TRAIL (50 ng/ml) for 12 h. After incubation, HDAC activity was measured by an HDAC activity ELISA 
assay kit. All data are expressed as the mean ± SD for triplicates. (D and E) HDAC3 regulates the expression of apoptosis-related proteins 
during co-treatment with delphinidin and TRAIL. (D) LNCaP cells were transfected with HDAC3 siRNA or a scrambled siRNA. Following 
transfection, cells were also exposed for a further 12 hours to delphinidin (30 µM) and/or TRAIL (50 ng/mL), and analyzed by western 
blot analysis with survivin, XIAP, cIAP-2, BID, BAX, BCL-2, HDAC3, p53, and acetylated p53 (Ac-p53) antibodies. (E) LNCaP cells 
were transfected with the empty plasmid or HDAC3 expression plasmid (F-HDAC3). Following transfection, cells were also exposed for a 
further 12 h to delphinidin (30 µM) and/or TRAIL (50 ng/mL), and the apoptotic factors above were analyzed by western blot analysis. (F 
and G) Combined treatment with TRAIL and delphinidin leads to apoptosis and cleavage of HDAC3 in prostate cancer cell lines. LNCaP 
(F) and Du145 cells (G) were treated with TRAIL (50 ng/ml) and/or delphinidin (30 µM) for 12 h, and then a western blot analysis was 
performed using PARP, HDAC3, or BID antibodies.
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TRAIL. HDAC3 activity (Fig. 5C) was also reduced 
by co-treatment with TRAIL and delphinidin. In the 
combined treatment with delphinidin and TRAIL, siRNA-
mediated suppression of HDAC3 more effectively blocked 
the expression of survivin, BCL-2, XIAP, BID, and cIAP-
2, and increased the expression of BAX compared with 
siRNA HDAC3 alone (Fig. 5D). Also, interestingly, the 
levels of acetylated p53 and total p53 increased more 
markedly in the combined treatment with delphinidin and 
TRAIL compared with either alone Fig. 5D. Conversely, 
exogenously expressed HDAC3 increased the expression 
of antiapoptotic factors survivin, BCL-2, XIAP, BID and 
cIAP-2 in a dose-dependent fashion, and remarkably 
decreased the expression of proapoptotic factors BAX, p53 
and acetylated p53, antagonizing the negative and positive 
effects of the delphinidin plus TRAIL combination (Fig. 
5E). Additionally, combined treatment with TRAIL and 
delphinidin led to apoptosis and cleavage of HDAC3 in 
TRAIL-resistant LNCaP cells as well as TRAIL-sensitive 
Du145 cells (Fig. 5F and 5G). Taken together, these results 
demonstrate that the cleavage of HDAC3 contributes to 
the sensitizing effect of delphinidin on TRAIL-mediated 
apoptosis, which involves the regulation of mitochondrial 
proteins, IAPs, p53, and acetylated p53.
Figure 6: HDAc3 cleavage is regulated by Dr5-mediated effector caspases activation in the delphinidin-induced 
sensitization of trAIL-mediated apoptosis. (A) DR5 expression is critical for the activation of caspases and cleavage of HDAC3 in 
the co-treatment of delphinidin and TRAIL. LNCaP cells were transfected with the scrambled siRNA or DR5 siRNA. Following transfection, 
cells were incubated for a further 12 h with delphinidin (30 µM) and/or TRAIL (50 ng/mL), and analyzed by western blot analysis with 
caspase-8, caspase-3, caspase-7, and HDAC3 antibodies. (b) Cleavage of HDAC3 depends on the activation of effector caspases. LNCaP 
cells were pretreated for 30 min with or without caspase-3/7 inhibitor DQMD (20 mM) before TRAIL (50 ng/ml) and/or delphinidin (30 
µM) treatment for 12 h. After incubation, western blot analysis was performed by using antibodies against caspase-7, caspase-3, cleaved 
caspase-3, and HDAC3. (c) TUNEL assay indicating the additive effects of TRAIL and delphinidin on induction of apoptosis in LNCaP 
cells (left). TUNEL-positive apoptotic cells were counted in five different high power fields (right). The data are expressed as percent 
TUNEL-positive cells. The data are expressed as the mean ± SD for triplicates. (D) Schematic diagram of apoptotic pathway induced by 
the combined treatment with TRAIL and delphinidin.
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HDAc3 cleavage is regulated by Dr5-mediated 
effector caspases activation and accelerated the 
delphinidin-induced sensitization of trAIL-
mediated apoptosis
As shown in Fig. 6A, in the combined treatment 
with delphinidin and TRAIL DR5 siRNA more effectively 
inhibited the activation of effector caspases (caspase-3 
and -7) and the cleavage of HDAC3 compared with the 
scrambled siRNA. Therefore, this result demonstrated 
that activity of effector caspases and HDAC3 cleavage 
is altered by DR5, which plays a critical role in the 
delphinidin-induced sensitization of TRAIL-mediated 
apoptosis. Because HDAC3 is caspase-dependent in some 
cell types, we examined the possible involvement of active 
effector caspases in HDAC3 cleavage. Pretreatment with 
the caspase 3/7 inhibitor DQMD inhibited the delphinidin 
and TRAIL-induced activation of caspase 3/7 and 
remarkably blocked truncation of HDAC3 (Fig. 6B), 
suggesting that HDAC3 is cleaved by effector caspases 
during co-treatment. DNA fragmentation represents a 
characteristic hallmark of apoptosis. TUNEL assay is 
an established method for detecting DNA fragments. To 
investigate whether combined treatment of delphinidin 
and TRAIL can induce apoptotic cell death through 
HDAC3, TUNEL staining was performed. As shown in 
Fig. 6C, apoptotic cell death by delphinidin and TRAIL 
combination treatment was significantly increased by 
HDAC3 siRNA (3.5-fold) compared with the scrambled 
siRNA (2.1-fold), suggesting that cleavage of HDAC3 
accelerates the sensitizing effect of delphinidin on TRAIL-
mediated apoptosis.
DIscUssION
TRAIL, also known as APO2L, is a member of the 
TNF family of death receptor ligands and has significant 
potential for use in cancer therapy because of its potent 
ability to selectively kill cancer cells while leaving 
normal cells unharmed [65]. The selectivity of TRAIL 
to trigger apoptosis in cancer cells has led to the clinical 
development of recombinant TRAIL and TRAIL-receptor 
agonists as an anticancer therapy. TRAIL-based therapies 
are now in Phase I and II clinical trials (www.clinicaltrials.
gov). However, TRAIL will probably not be viable as a 
single agent since the majority of tumor cells are resistant 
to TRAIL. Combination therapy (with chemotherapy 
or radiation) is therefore essential for the use of TRAIL 
against refractory tumors.
In our current report, we find for the first time 
that delphinidin, a major anthocyanidin, is capable of 
sensitizing highly resistant prostate cancer cells to TRAIL-
mediated apoptosis. Caspase-dependent pathways of 
apoptosis are involved in this process, as evidenced by a 
strong induction of caspase-3/7, caspase-8 and caspase-9 
activity. This finding suggests that prostate cancer cells are 
capable of amplifying apoptotic signaling initiated by DR’s 
through the recruitment of the mitochondrial pathway, as 
observed in other cell types. Given that TRAIL is known 
to trigger apoptosis through binding to its cell surface 
death receptors, DR4 and DR5, the expression levels of 
these death receptors may be critical to determining the 
intensity and/or duration of TRAIL-induced apoptotic 
signaling [8, 9, 66]. We recently showed that the DR5 
up-regulating agent, neobavaisoflavone, effectively 
stimulates TRAIL-mediated apoptosis in prostate cancer 
cells via the intrinsic pathway [67]. In this study, we find 
that delphinidin increases the protein level of DR5 in 
prostate cancer cells. A siRNA-mediated DR5 knockdown 
effectively inhibits the apoptosis induced by delphinidin 
plus TRAIL, confirming the functional significance of 
DR5 up-regulation in delphinidin-stimulated TRAIL-
mediated apoptosis. In addition, combined treatment 
with delphinidin and TRAIL transcriptionally regulates 
expression of anti-apoptotic and pro-apoptotic molecules 
as well as DR5. Notably, co-treatment with delphinidin 
and TRAIL significantly reduced the mRNA expression 
level of MCL-1, XIAP and cIAP-2. Human MCL-1 is an 
anti-apoptotic member of the BCL-2 protein family with 
similar BH (BCL-2 homology)-multidomain structures 
as BCL-2 and BCL-XL [16, 68]. Recently, it has been 
reported that increased MCL-1 expression likely confers 
additional protection against tBID in TRAIL-treated BAX-
deficient cells [19]. It follows that in cells with elevated 
MCL-1 expression, tBID is bound by MCL-1 [69], 
and all of tBID’s proapoptotic activities are inhibited. 
Thus, we speculate that down-regulation of MCL-1 
by delphinidin plus TRAIL might play a critical role in 
delphinidin-stimulated TRAIL-mediated apoptosis. Also, 
the potent inhibitors of caspases, XIAP, cIAP-2, and 
survivin, are down-regulated by delphinidin plus TRAIL. 
Furthermore, it is reported that salirasib, an S-farnesyl 
cysteine analog, reduces survivin mRNA expression 
in human hepatocarcinoma cell lines, and protein 
expression of survivin markedly decreases after 48 h of 
treatment with 150 mM of salirasib, coinciding with the 
beginning of TRAIL sensitization. It is therefore tempting 
to speculate that salirasib-induced inhibition of survivin 
has an important role in this process [33]. Therefore, our 
data suggest that sensitization of LNCaP cells to TRAIL-
induced apoptosis by delphinidin occurs through DR5 up-
regulation and caspase-dependent mitochondrial pathways 
(Fig. 6D).
HDAC3 is an important component of nuclear 
receptor co-repressor (N-CoR)-silencing mediator for 
retinoid and thyroid receptor (SMRT) co-repressor 
complexes that include G protein suppressor pathway 
2 (GPS2), transducin β-like 1 (TBL1), and transducin 
β-like X-linked receptor 1 (TBLR1) [70]. We find that 
cleavage of HDAC3 contributes to the sensitizing effect 
of delphinidin on TRAIL-mediated apoptosis involving 
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the regulation of mitochondrial proteins. HDAC3 is 
cleaved, and cleaved HDAC3 localizes to the cytoplasm 
and can no longer deacetylate histones on the promoters 
of its proapoptotic targets upon apoptosis induction. 
Histones on these promoters can become hyperacetylated, 
thereby allowing the transcriptional activation of these 
proapoptotic genes and cell progression into apoptosis 
[51]. Truncated HDAC3, which is generated by caspase-7 
cleavage during the early phase of osmotic stress, binds 
to the c-JUN promoter region in a c-JUN-dependent 
manner, deacetylates histones, and thereby represses 
c-JUN transcription. The abrogated c-JUN expression, 
which down-regulates c-JUN activation occurring during 
the early stage of exposure to stress, promotes osmotic 
stimulation-induced cell apoptosis [49]. Thus, we 
speculate that delphinidin-stimulated TRAIL-mediated 
apoptosis is accelerated by the transcriptional activation of 
proapoptotic genes via cleavage of HDAC3. In addition, 
we reveal that co-treatment with delphinidin and TRAIL 
induces DR5 up-regulation and downstream cleavage of 
HDAC3 by effector caspases. Similar to the repression 
of c-JUN by cleaved HDAC3, HDAC4 is cleaved in 
a caspase-3-dependent manner [71, 72], causing the 
N-terminal fragment of HDAC4 to translocate into the 
nucleus and to represses transcription of myocyte enhancer 
factor-2C (MEF2C) [72]. We believe that the consistency 
of mechanistic action supports our model suggesting 
that HDAC3 cleavage by the effector caspases critically 
contributes to delphinidin-facilitated TRAIL-mediated 
apoptosis.
In conclusion, we demonstrate for the first time that 
a combination of delphinidin and TRAIL can effectively 
induce apoptosis in prostate cancer cells. Also, we find 
that delphinidin-mediated TRAIL sensitization in prostate 
cancer cells seem to be associated with activation of 
effector caspases via induction of the DR5 pathway, 
leading to HDAC3 cleavage-dependent mitochondrial 
apoptosis. Therefore, our study provides a possible 
therapeutic application of delphinidin and TRAIL for 
treatment of prostate cancers that are resistant to TRAIL.
mAtErIALs AND mEtHODs
cell culture, reagents, and antibodies
Human prostate LNCaP and Du145 cells were 
obtained from the American Type Culture Collection 
(Manassas, VA) and cultured in RPMI supplemented with 
10% fetal bovine serum (FBS; Gibco-BRL, MD) and 1% 
antibiotic-antimycotic solution in a humidified 5% CO2 
atmosphere at 37°C. Antibodies against cleaved caspase-3, 
caspase-7, caspase-8, caspase-9, PARP, Survivin, XIAP, 
cIAP-2, BID, BAX, DR5, BCL-2 and acetylated p53 
(Ac-p53) antibodies were purchased from Cell Signaling 
Technology (Beverly, MA). Anti-HDAC1, HDAC2, 
HDAC3, HDAC8, FLAG, p53, and actin antibodies were 
purchased from Santa Cruz Biotechnology (Dallas, TX). 
Anti-FLAG and β-actin antibodies were purchased from 
Sigma-Aldrich (St. Louis, MO). The anti-mouse or anti-
rabbit secondary antibodies were purchased from Pierce 
(Rockford, IL). Delphinidin and TRAIL were obtained 
from Sigma-Aldrich (Fig. 1A). 
caspase assays
Delphinidin and TRAIL-mediated caspase activation 
was evaluated using Caspase-Glo 3/7, 8, and 9 kits 
(Promega, Madison, WI) according to the manufacturer’s 
instructions. Briefly, LNCaP cells were plated in 96-well 
clear-bottom plates (Lonza, Basel, Switzerland). The 
cells were treated with TRAIL with/without delphinidin. 
After 24 h, assay reagent (100 μl) was added to each well. 
The plate was incubated in the dark for 30–60 min, and 
luminescence was measured using a SpectraMAX 250 
Optima plate reader (Molecular Device Co., Sunnyvale, 
CA).
Western blot analyses
Western blot analysis was carried out as previously 
described [73]. Protein extracts were prepared from 
TRAIL with/without delphinidin treated cells, and the 
indicated proteins in the figures were determined using 
western blot analyses. LNCaP cells were treated with 
TRAIL with/without delphinidin. Cells were collected 
24 h after treatment, washed once with PBS, and extracts 
were prepared with lysis buffer [50 mM Tris-Cl (pH 7.5), 
150 mM NaCl, 1% NP40, 10 mM NaF, 10 mM sodium 
pyrophosphate, and protease inhibitors]. Protein extracts 
were separated using 10% SDS–polyacrylamide gels, 
and transferred to nitrocellulose membranes. Blots were 
blocked for 1 h and then incubated with the primary 
antibody for 2 h at room temperature or overnight at 4°C, 
and processed with HRP-conjugated secondary antibody. 
Protein bands were visualized using film developer.
mtt assays to measure cytotoxicity
The cytotoxicity of LNCaP and Du145 cells was 
determined using conventional MTT reduction assays. 
Briefly, cells (4,000 cells/well) were plated in 96-
well white-walled, clear-bottom plates (Lonza, Basel, 
Switzerland) and incubated for 24 h at 37°C. Cells were 
treated with vehicle (DMSO), increasing concentrations 
of delphinidin (0 - 90 μM), or increasing concentrations of 
TRAIL (0, 50, 100, and 150 ng/ml). After 4, 8, and 12 h, 
100 μl of assay reagent was added to each well. The plate 
was incubated in the dark for 15 min, and luminescence 
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was measured using a SpectraMAX 250 (Molecular 
Device Co., Sunnyvale, CA). All MTT assay data are 
presented as the mean (± SD) of three independent 
experiments.
rNA extraction and quantitative rt-Pcr
Total RNA was isolated with the RNA Easyspin kit 
according to the instructions of the manufacturer (Intron 
Biotechnology, Seongnam, Korea). Total RNA from each 
sample was reverse transcribed with random primers 
using a StrataScriptTM reverse transcriptase kit (Qiagen 
Inc., Valencia, CA) according to the manufacturer’s 
protocol. Quantitative real-time RT-PCR (qRT-PCR) was 
performed using a SYBR® Premix Ex TaqTM Kit (TaKaRa, 
Shiga, Japan) with forward and reverse primers for each 
gene. Primers for amplification of the DR5 transcript 
were 5’-TGACGGGGAAGAGGAACTGA-3’ and 
5’-GGCTTTGACCATTTGGATTTGA-3’. Primers for 
p21/CDKN1A amplification were 5’-GTGGAGAGCATT 
CCATCCCT-3’ and 5’-TGGATGCAGCTTCCTCT 
CTG-3’. Primers for BAX amplification were 
5’-TCTACTTTGCCAGCAAACTGGTGC-3’ and 
5’-TGTCCAGCCCATGATGGT TCTGAT-3’. Primers 
for BCL2 amplification were 5’-CATGCTGGGG 
CCGTACAG-3’ and 5’-GAACCGGCA 
CCTGCACAC-3’. Primers for Survivin amplification 
were 5’-TGCCTGGCAGCCCTTTC-3’ and 5’-CCTCCA 
AGAAGGGCCAGTTC-3’. Primers for MCL1 
amplification were 5’-GGGCAGGATTGTGAC 
TCTCATT-3’ and 5’-GATGCAGCTTTCTTGG 
TTTATGG-3’. Primers for XIAP amplification 
were 5’-AGTGGTAGTCCTG TTTCAGCATCA-3’ 
and 5’-CCGCACGGTATCTCCTTCA-3’. 
Primers for cIAP2 amplification were 5’-
TCC GTCAAGTTCAAGCCAGTT-3’ and 
5’-TCTCCTGGGCTGTCTGATGTG-3’. The quantitative 
real-time PCR was carried out as previously described 
[74]. Briefly, 1 μl of cDNA from the RT reaction was 
added to 20 μl of the real-time quantitative polymerase 
chain reaction mixture containing 10 μl of 2× SYBR® 
Premix Ex TaqTM, and 0.2 μM forward and reverse 
primers. PCRs were carried out in ABI 7500 Real-Time 
PCR System (Applied Biosystems, Carlsbad, CA). The 
samples were incubated at 95°C for 10 min, followed by 
40 cycles at 95°C for 30 s and then at 60°C for 1 min. 
All samples were normalized to human GAPDH and 
expressed as fold induction. All reactions were done 
in triplicate. Relative expression levels and SDs were 
calculated using the comparative method.
sirNA transfection 
siRNAs in this study were purchased from Bioneer, 
Korea and had the following siRNA sequences: siRNA 
DR5 was 5’-AUCAGCAUCGUGUACAAGGUGUCCC; 
siRNA BAX was 5’-AAGACCCGCGCCGAGGUGAAG; 
siRNA HDAC1 was 5’-GAGUCAAAACAGAGGAUGA; 
siRNA HDAC2 was 5’-GACGGAAACUGAGCUCAGU; 
siRNA HDAC3 was 5’-GAGCUUCAAUAUCCCUCUA; 
siRNA HDAC8 was 5’-GUGUCUUAAGUACAUCCUU; 
siRNA BAX was 5’-GCUGGACAUUGGACUUCCU. 
LNCaP cells were cultured in each well of 6-well plates 
for 12 h. For siRNA transfection, Lipofectamine 2000 
(Invitrogen) was added to 100 pmol siRNA in a final 
volume of culture medium. After 36 h of transfection, cells 
were treated with delphinidin and TRAIL for 12 h.
DAPI staining
Untreated control cells and cells treated with the 
delphinidin and/or TRAIL were washed with PBS and 
fixed with 3.7% paraformaldehyde (Sigma) in PBS for 
10 min at room temperature. The fixed cells were washed 
with PBS and stained with a 1 mg/mL DAPI (Sigma) 
solution for 10 min at room temperature. The cells were 
washed two more times with PBS and examined using a 
fluorescence microscope (BX50; Olympus, Tokyo, Japan).
HDAc activity assay
A histone deacetylase (HDAC) activity assay was 
carried out according to the manufacturer’s instructions 
by using an available commercial kit (BioVision 
Biotechnology, Milpitas, CA). For specific HDAC activity 
assays, HDAC1, HDAC2, HDAC3, and HDAC8 proteins 
were immunoprecipitated from LNCaP nuclear extracts by 
using anti-HDAC1, anti-HDAC2, anti-HDAC3, and anti-
HDAC8 antibodies. Immunoprecipitated complexes were 
collected and washed with an HDAC assay buffer (50 
mmol/L Tris pH 8.0, 10% glycerol, 0.1 mmol/L EDTA).
tUNEL assay
To detect cellular apoptosis DNA fragmentation was 
evaluated by a TUNEL assay using HT Titer TACS Assay 
Kit (Trivigen, Gaithersburg, MD, Cat No., 4822-96-K), 
according to the manufacturer’s instructions. Briefly, the 
cells were fixed with 3.7% buffered formaldehyde solution 
for 7 min, washed with PBS, permeabilized with 100% 
methanol for 20 min, washed twice with PBS, digested 
with proteinase K for 15 min, quenched with 3% hydrogen 
peroxide, washed with distilled water, labeled with 
deoxynucleotidyl transferase, incubated at 37°C for 90 
min, and treated with stop buffer. The cells were incubated 
with a TACS-Sapphire substrate, and the colorimetric 
reaction was stopped with 0.2N HCl after 30 min. The 
cells were incubated with a TACS-Sapphire substrate, 
and the colorimetric reaction was stopped with 0.2N HCl 
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after 30 min. The cells were visualized by fluorescence 
microscopy. TUNEL positive cells were counted in at least 
five microscopic frames of the sections.
statistical analyses
Statistical analysis was performed using Student’s 
t-tests and the SPSS program (SPSS Inc., Chicago, IL). A 
statistical threshold of P < 0.05 was considered statistically 
significant.
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